Ventures Vii, Llc Vivo Net Worth

The estimated Net Worth of Ventures Vii, Llc Vivo is at least $10.3 Million dollars as of 5 November 2015. Ventures Vivo owns over 390,572 units of MEI Pharma Inc stock worth over $9,552,577 and over the last 10 years Ventures sold MEIP stock worth over $718,652.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Vivo MEIP stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the MEI Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Ventures sold 390,572 units of MEIP stock worth $718,652 on 5 November 2015.

The largest trade Ventures's ever made was selling 390,572 units of MEI Pharma Inc stock on 5 November 2015 worth over $718,652. On average, Ventures trades about 195,286 units every 0 days since 2015. As of 5 November 2015 Ventures still owns at least 3,163,105 units of MEI Pharma Inc stock.

You can see the complete history of Ventures Vivo stock trades at the bottom of the page.

What's Ventures Vivo's mailing address?

Ventures's mailing address filed with the SEC is 575 HIGH STREET, SUITE 201, PALO ALTO, CA, 94301.

Insiders trading at MEI Pharma Inc

Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L..., and Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.

What does MEI Pharma Inc do?

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.

Complete history of Ventures Vivo stock trades at MEI Pharma Inc

MEI Pharma Inc executives and stock owners

MEI Pharma Inc executives and other stock owners filed with the SEC include:

• Daniel Gold,
  President, Chief Executive Officer, Director
• David Urso,
  Chief Operating Officer, General Counsel
• Dr. Daniel P. Gold,
  Pres, CEO & Director
• Brian Drazba,
  Chief Financial Officer, Secretary
• David M. Urso B.A., Esq., J.D.,
  COO & Gen. Counsel
• Robert Mass,
  Chief Medical Officer
• Brian G. Drazba B.A., CPA, CPA,
  CFO & Sec.
• Dr. Richard G. Ghalie,
  Chief Medical Officer
• Dr. Robert D. Mass,
  Strategic Advisor
• Charles Baltic,
  Independent Director
• Nicholas Glover,
  Independent Director
• Kevan Clemens,
  Independent Director
• Frederick Driscoll,
  Independent Director
• Tamar Howson,
  Independent Director
• Cheryl Cohen,
  Director
• Brian Powl,
  Senior Vice President of Marketing
• Tina Clark Beamon Esq., J.D.,
  Chief Compliance Officer
• Dr. Karen E. Potts Ph.D.,
  Sr. VP of Regulatory Affairs
• Dr. Ofir Moreno,
  Sr. VP of Pharmaceutical Sciences
• Jamie A. Tereschuck,
  VP of HR
• David A. Walsey J.D., L.L.M.,
  VP of IR & Corp. Communications
• Leaf Ventures Ii, L.P.New L...,
  
• Ventures V, Llc Vivo,
  
• Leah Rush Cann,
  Director
• Thomas M. Zech,
  Chief Financial Officer
• William Dodge Rueckert,
  Director
• Ventures Vii, Llc Vivo,
  
• Christine Anna White,
  Director
• Ventures V, Llc Vivo Ventur...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Ventures Vii, Llc Vivo Vent...,
  
• Josiah T El Coronado Holdin...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Josiah T Austin,
  10% owner
• Bryan Williams,
  Director
• Ltd Novogen,
  10% owner
• Sujay Kango,
  
• Richard G Ghalie,
  Chief Medical Officer
• Thomas C Reynolds,
  
• Funds Management Lp Anson A...,
  
• Funds, Lp Cable Car Capital...,
  
• Steven D Wood,
  
• James P Flynn,